Medical and Pharmaceutical

Sri Lanka’s pharmaceutical market is valued at USD 750 million in 2025 and is growing at a 5-year CAGR of 4.1%, reflecting strong and steady demand. With 85% of pharmaceutical needs met through imports, there is significant potential for export-oriented investments in generic drugs, specialty medicines, biologics, vaccines, and Ayurvedic products. Supported by government incentives, regulatory oversight, strategic location, and competitive costs, Sri Lanka offers a thriving environment for foreign investors seeking sustainable, profitable pharmaceutical ventures with regional market access.

Key Facts

  • Projected growth rate accelerates to 11.07% by 2027, reflecting strong demand and investment potential
  • 85% of pharmaceutical needs are currently met through imports, indicating significant opportunities for export-oriented investments
  • Key growth Areas – Generic drugs, specialty pharmaceuticals, biologics, vaccines, and Ayurvedic/botanical medicines
  • Proposed manufacturing zone dedicated to pharmaceuticals in the south of the country
  • The National Medicines Regulatory Authority (NMRA) ensures safety, efficacy, and quality control of pharmaceutical products, with clear guidelines for foreign investors
  • Opportunities exist for technology transfer, R&D partnerships, and joint ventures with local or regional companies
  • Competitive labor costs, proximity to Asian supply chains, government incentives, and export potential to regional markets

Priority Areas

Priority Areas

 

Pharmaceuticals, Medicinal Chemical and Botanical Products Manufacturing Facilities

  • Formulation of antibiotics
  • Manufacture of antibiotics
  • Formulation of Other products (chemical/plant extracts)
  • Manufacture of other products (chemical/plant extracts)
  • Manufacture of three types of main Radio-pharmaceuticals commonly used in cancer treatment (I-131, TC-99, F-18). 
  • Manufacture of Cosmetic products
  • Manufacture of Ayurvedic drugs
  • Manufacture or Assembling of medical devices

     Related Ancillary Facilities

  • R&D facilities, including biotechnology research and production
  • Laboratory testing facilities
  • Active Pharmaceutical Ingredients (API) Production
  • Pharma R&D and Innovation Centers
  • Export-Oriented Production
  • Digital Pharma and E-Health Solutions

Key Markets

 
  1. India
  2. Japan
  3. Maldives
  4. Russian Federation
  5. Kazakhstan
  6. United Arab Emirates
  7. Yemen
  8. Malaysia
  9. Australia
  10. United Kingdom
Apply Online for Investment
Scroll to Top